Skip to main content
. 2025 Apr 25;6(4):e250905. doi: 10.1001/jamahealthforum.2025.0905

Figure 2. Base-Case Analysis Showing 10-Year Fiscal Impact of Glucagon-Like Peptide-1 Receptor Agonists on Medicare Expenditures for Obesity Treatment.

Figure 2.

This figure presents the projected 10-year fiscal impact of glucagon-like peptide-1 receptor agonists on Medicare expenditures for obesity treatment from 2026 to 2035. The bars represent 3 key components of fiscal impact: medication costs, obesity-related health savings, and net spending.